VSEE VSEE
Company Profile ↓Company Overview
VSEE (VSEE) is a publicly traded company listed on with a market capitalization of $1.66M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 31.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $14.62M (+40.3% YoY); net profit $-14.71M.
- Trailing 12 Months Year-on-year growth — revenue +40.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 31.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 31.85% |
| 1 Year: | 40.27% |
Stock Price Performance
| 1 Year: | -95.85% |
| 6 Months: | -85.66% |
| 3 Months: | -72.57% |
| 1 Month: | -54.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)28.24 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 31.9% over 5 years.
CONS
- Trading 96.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 1.58M | 1.27M | 1.43M | 1.62M | 1.71M | 3.35M | 3.86M | - | 3.39M | 3.98M | 3.93M | 3.16M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 1.43M | - | - | 1.91M | 2.09M | 1.96M |
| Gross Profit | - | - | - | - | - | 1.00M | 797.19K | 954.32K | 1.23M | 777.00K | 2.78M | 2.43M | - | 1.59M | 2.07M | 1.83M | 1.20M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 5.54M | - | - | 4.13M | 5.27M | 4.17M |
| Operating Income | -5.00K | -180 | -543.18K | -722.16K | -1.13M | -715.86K | -689.84K | -353.07K | 104.06K | -932.52K | -58.29M | -3.11M | - | -2.25M | -2.06M | -3.44M | -2.97M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -4.14M | - | - | 1.14M | -6.07M | -1.81M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | -379.63K | - | - | 755.87K | 1.08M | 113.10K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -4.47M | - | - | -289.75K | -7.80M | -2.58M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 1.15M | - | - | 0 | 50.44K | 23.74K |
| Net Income | -5.00K | -180 | -527.36K | -659.46K | -820.76K | -529.96K | -503.32K | -189.76K | 62.77K | -634.12K | -53.92M | -5.62M | - | -2.61M | -289.75K | -7.85M | -2.60M |
| Diluted EPS | - | - | -0.04 | -0.04 | -0.05 | -0.05 | -0.11 | -0.02 | 0.01 | -0.12 | -3.58 | - | - | -0.16 | -0.02 | - | -0.05 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 6.38M | 5.77M | 10.42M | 14.62M |
| Cost of Revenue | - | 1.54M | 1.93M | 3.24M | 7.26M |
| Gross Profit | - | 4.84M | 3.83M | 7.18M | 7.36M |
| Operating Expenses | - | 6.30M | 5.62M | 11.86M | 16.94M |
| Operating Income | - | -1.46M | -1.79M | -4.68M | -9.58M |
| EBITDA | - | -1.59M | -1.69M | -57.75M | -9.18M |
| Interest Expense | - | 31.87K | 191.32K | 211.46K | 2.81M |
| Pretax Income | - | -1.62M | -1.89M | -59.34M | -14.64M |
| Tax Provision | - | -694.36K | 1.84M | -1.64M | 68.43K |
| Net Income | - | -836.21K | -3.76M | -57.70M | -14.71M |
| Diluted EPS | 0.03 | -0.06 | -0.26 | - | -0.73 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2021 | Dec 2021 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 2.61M | - | - | 805.79K | - | 78.59M | 22.30M | 19.99M | 22.41M |
| Current Assets | - | - | 759.78K | - | - | 802.13K | - | - | - | 3.02M | 8.37M |
| Cash & Equivalents | - | - | 230.66K | - | - | 118.73K | - | - | - | 326.12K | 5.27M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | 389.45K | - | - | 603.48K | - | - | - | 1.72M | 2.52M |
| Total Liabilities | - | - | 2.61M | 3.92M | 5.04M | 5.11M | 5.64M | 25.48M | 21.37M | 20.01M | 16.96M |
| Current Liabilities | - | - | 2.61M | 3.92M | 5.04M | 5.11M | - | 24.12M | 20.23M | 19.01M | 16.24M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | 517.13K | - | - | 543.00K | - | - | - | 9.55M | 3.26M |
| Total Equity | 0 | - | 360.72K | -1.10M | -1.77M | -3.97M | -4.20M | 53.10M | 933.13K | -18.49K | 5.45M |
| Shares Outstanding | - | - | 14.69M | - | - | 14.69M | - | - | - | 16.30M | 33.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -825.78K | -632.60K | -5.79M | -3.45M |
| Investing Cash Flow | - | - | -4.33K | -26.14K | -29.93K |
| Financing Cash Flow | - | 710.00K | 525.00K | 6.02M | 8.42M |
| Capital Expenditure | - | - | -4.33K | -55.27K | -29.93K |
| Free Cash Flow | - | -825.78K | -636.93K | -5.84M | -3.48M |
| Net Change in Cash | - | -115.78K | -111.93K | 207.38K | 4.94M |
| Share Buybacks | - | 110.47M | 6.80M | 5.15K | 44 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 75.8% | 66.5% | 68.9% | 50.3% |
| Operating Margin % | - | -23.0% | -31.0% | -44.9% | -65.6% |
| Net Margin % | - | -13.1% | -65.3% | -553.7% | -100.6% |
| ROE % | - | -231.8% | 94.7% | 312,105.2% | -269.8% |
| ROCE % | - | 72,012.2% | 41.6% | -476.8% | -155.4% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VSEE
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNSnM2MDhDRk5FYUNjYUk5QlVWZ19ER19yWDgxX2dLbnVqbGZSS2lWb0EtME5IaU1DVWRkM0dheXJRLThlNjB2c3NHVTFSenFvMERQVVJpRnFFU0dqR255b1EweTBiM2tUWVliS1FUclI5eUpTVWlvOGRxX0dvc3lFSjJVNzdjQk9MTlRfYT…
VSee Health's Network Expanded From 3 Hospitals in 2024 to 58 in 2026 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOSTNSRzdFZ1ptRmppRjJxaEhySVRuSGxWSmlZRWQxQjdtRXcyWXZMYkR1VkozbHEwXy1zZ3J1ZGM0NGo1TlZidjBNMXhPcmVXamZFcUJ3THFlandYbDd0NEFHUHM3aFJjeTFvdU05Qi1NN1ZBclpsbDRCRVZuOFhHbWQ3NkdOaHhnMDQzcF…
VSee Health proposes 80-for-1 reverse stock split to retain listing - Investing.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOQUp1UnNjU1Vscjl0czhKc1NDaHgwSlVvVWZCMS14OUkxQkN2UG0tNm9QY0dkekpoMWJnRnE1TEhuUFVCNmstYkhxOVR1NnMwY1NqZlBGUEtJY1ZtXzZjZTBjLWFOZ0Y4WHhqWmtpVXdVXzdqNzdGbFNzZV9xNEZUSklCNVVaY0h6RHJaME…
Monday's session: most active stocks - ChartMill
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQSFBib2dQZGV5c0tFbXJuU0ptdHBOdFd4dmFuRnE1NmpKQWo3cHhRWndEc1UzMllDY19vTER1aTBPV1FDanVKdXVucHp2UjJ3cFVNWWI2SWJxMVJfOGNJUEI0OVdKaWQ0SFhqTHIzS2pqeHl5b0hsdU15aVZzNGxfRjg4NmMyMTZsMnJaRn…
VSee Health Outlines AI-Enabled Enterprise Infrastructure Strategy for Hospital Operations - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQVk5VQUNWbEhFNDBuR1hTanNrbzd1bGU0NU9vQnBuQ0JfcFAxZ3RVRGdSMVktVHZ6VkJzNF9wMVBoRjd5SVBuQ0FYNTlFY0hRWVJZeGVVMzdLWVBrZGRqaUtwSWwzZDdBVlFzNXlJN3h2dS1qUE5iV19BODY2Um5fR0k4dHE3YnhjbFV0N3…
VSee Health, Inc. Revenue Breakdown – NASDAQ:VSEE - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5KblBhQUltemhNd0J4NklBa2dEcU94bDFpSHB5ZDRIZEVBellBSEVQM1VNd1M2ZnlSUXlyQjJ6RGphb18wMGtuNjcyaDRXbUQ4NlVQR2o5TE5ZUjRKV1ZCQjBSYmZabkJWRENyQUJZTWJhbEh0Z2VF?oc=5" target="_blank">VSee He…
VSEE — Frequently Asked Questions
What is the current share price of VSEE?
As of 2026-08-05 17:25 PDT, VSEE trades at $0.05 on NASDAQ/NYSE. Its 52-week range is $0.05 to $1.39.
What is the market capitalisation of VSEE?
VSEE has a market capitalisation of $1.66M on NASDAQ/NYSE.
What is the P/E ratio of VSEE?
VSEE trades at a trailing price-to-earnings (P/E) ratio of -0.07. Its price-to-book (P/B) ratio is 0.30.
Is VSEE a good stock to buy?
This page provides a data-driven analysis of VSEE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.